• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Psychiatric Disorders - Pipeline Review, H2 2012 Product Image

Psychiatric Disorders - Pipeline Review, H2 2012

  • ID: 2298829
  • October 2012
  • 428 pages
  • Global Markets Direct

Psychiatric Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Psychiatric Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Psychiatric Disorders.
- A review of the Psychiatric Disorders products under development by companies READ MORE >

2
List of Tables 14
List of Figures 20
Introduction 21
REPORT COVERAGE 21
Psychiatric Disorders Overview 22
Therapeutics Development 23
An Overview of Pipeline Products for Psychiatric Disorders 23
Psychiatric Disorders Therapeutics under Development by Companies 25
Psychiatric Disorders Therapeutics under Investigation by Universities/Institutes 38
Late Stage Products 47
Comparative Analysis 47
Mid Clinical Stage Products 48
Comparative Analysis 48
Early Clinical Stage Products 49
Comparative Analysis 49
Discovery and Pre-Clinical Stage Products 50
Comparative Analysis 50
Psychiatric Disorders Therapeutics – Products under Development by Companies 51
Psychiatric Disorders Therapeutics – Products under Investigation by Universities/Institutes 69
Companies Involved in Psychiatric Disorders Therapeutics Development 86
Bristol-Myers Squibb Company 86
F. Hoffmann-La Roche Ltd. 87
Abbott Laboratories 88
NsGene A/S 89
Amgen Inc. 90
Sanofi-Aventis 91
Eli Lilly and Company 92
Athersys, Inc. 93
GlaxoSmithKline plc 94
Tekmira Pharmaceuticals Corp. 95
Alkermes, Inc. 96
Dainippon Sumitomo Pharma Co., Ltd. 97
Taisho Pharmaceutical Co., Ltd. 98
Sangamo BioSciences, Inc. 99
Otsuka Pharmaceutical Co., Ltd. 100
Takeda Pharmaceutical Company Limited 101
Albany Molecular Research, Inc. 102
CardioVascular BioTherapeutics, Inc. 103
BioLineRx, Ltd. 104
Avineuro Pharmaceuticals, Inc. 105
Alexza Pharmaceuticals, Inc. 106
Zogenix, Inc. 107
Novartis AG 108
Aphios Corporation 109
AcelRx Pharmaceuticals, Inc. 110
EnVivo Pharmaceuticals 111
Acorda Therapeutics, Inc. 112
Astellas Pharma Inc. 113
Eisai Co., Ltd. 114
Gedeon Richter Plc. 115
H Lundbeck A/S 116
Mitsubishi Tanabe Pharma Corporation 117
Nippon Shinyaku Co., Ltd. 118
Pfizer Inc. 119
Sigma-Tau S.p.A. 120
Zydus Cadila Healthcare Limited 121
Shire Plc 122
NuPathe Inc. 123
Oxygen Biotherapeutics, Inc. 124
Addex Pharmaceuticals 125
Evotec Aktiengesellschaft 126
FAES Farma SA 127
GW Pharmaceuticals plc 128
Anavex Life Sciences Corp. 129
AEterna Zentaris Inc. 130
Neuralstem, Inc. 131
AVANIR Pharmaceuticals 132
Karo Bio 133
Lpath, Inc. 134
Neuren Pharmaceuticals Limited 135
NeuroSearch A/S 136
Catalyst Pharmaceutical Partners, Inc. 137
NovaDel Pharma, Inc. 138
Nuvo Research Inc. 139
Corcept Therapeutics Incorporated 140
ACADIA Pharmaceuticals Inc. 141
ARYx Therapeutics 142
RegeneRx Biopharmaceuticals, Inc. 143
Dongwha Pharm Co., Ltd. 144
Biotie Therapies Corp. 145
Transition Therapeutics Inc. 146
Allon Therapeutics Inc. 147
Suven Life Sciences Ltd. 148
Newron Pharmaceuticals S.p.A. 149
Stem Cell Therapeutics Corp. 150
Rexahn Pharmaceuticals, Inc. 151
NeuroVive Pharmaceutical AB 152
Jiangsu Nhwa Pharma Corporation 153
Mithridion, Inc. 154
Intas Pharmaceuticals Ltd. 155
M et P Pharma AG 156
Spectrum Pharmaceuticals, Inc. 157
D-Pharm Ltd. 158
Avanti Therapeutics 159
Argolyn Bioscience, Inc. 160
Arbor Pharmaceuticals, Inc. 161
KeyNeurotek Pharmaceuticals AG 162
Snowdon Inc. 163
Domain Therapeutics 164
Ironwood Pharmaceuticals, Inc. 165
Abiogen Pharma S.p.A. 166
Celon Pharma Sp. z o.o. 167
Critical Pharmaceuticals Limited 168
Curemark, LLC 169
Indena S.p.A. 170
Affectis Pharmaceuticals AG 171
Global Health Ventures Inc. 172
CoLucid Pharmaceuticals, Inc. 173
Trevena, Inc. 174
Supernus Pharmaceuticals, Inc. 175
Psylin Neurosciences, Inc. 176
Remedy Pharmaceuticals, Inc. 177
Pantarhei Bioscience BV 178
PsychoGenics, Inc. 179
Ferrer Internacional S.A. 180
Indus Biotech Private Limited 181
Hydra Biosciences, Inc. 182
Theraptosis S.A. 183
Adamas Pharmaceuticals, Inc. 184
Theracos, Inc. 185
NeuroNascent, Inc. 186
Azevan Pharmaceuticals, Inc. 187
vasopharm GmbH 188
CeNeRx BioPharma, Inc. 189
Concert Pharmaceuticals, Inc. 190
Omeros Corporation 191
Intra-Cellular Therapies, Inc. 192
Peptron, Inc. 193
Targacept, Inc. 194
Ortho-McNeil Pharmaceuticals, Inc. 195
N-Gene Research Laboratories, Inc. 196
Vanda Pharmaceuticals Inc. 197
KYORIN Pharmaceutical Co., Ltd. 198
Galenea Corp. 199
Marinus Pharmaceuticals, Inc. 200
M's Science Corporation 201
Encore Therapeutics Inc. 202
BrainCells Inc. 203
Adamed Sp. z o.o. 204
NeuroTherapeutics Pharma Inc. 205
Cannasat Therapeutics, Inc. 206
Kuhnil Pharmaceutical Co., Ltd. 207
Dr. Falk Pharma GmbH 208
Lee's Pharmaceutical Holdings Limited 209
Sihuan Pharmaceutical Holdings Group Ltd. 210
KemPharm, Inc. 211
Heptares Therapeutics Ltd. 212
Ascendis Pharma A/S 213
Envoy Therapeutics, Inc. 214
Embera NeuroTherapeutics, Inc. 215
ArmaGen Technologies, Inc. 216
Sinapis Pharma, Inc 217
BHR Pharma, LLC. 218
Pherin Pharmaceuticals, Inc. 219
Celtic Pharmaceutical Holdings L.P. 220
Beech Tree Labs, Inc. 221
Cognosci, Inc. 222
Reviva Pharmaceuticals Inc. 223
Mayne Pharma Limited 224
Mt Cook Pharma. Inc. 225
FunZyme BioTechnologies S.A. 226
Naurex, Inc. 227
STATegics, Inc. 228
PharmaNeuroBoost N.V. 229
Psychiatric Disorders – Therapeutics Assessment 230
Assessment by Monotherapy Products 230
Assessment by Combination Products 231
Assessment by Route of Administration 232
Assessment by Molecule Type 234
Drug Profiles 236
zicronapine - Drug Profile 236
Product Description 236
Mechanism of Action 236
R&D Progress 236
nalmefene - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
lurasidone hydrochloride - Drug Profile 240
Product Description 240
Mechanism of Action 240
R&D Progress 240
aripiprazole - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 251
mifepristone - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
mirtazapine - Drug Profile 329
Product Description 329
Mechanism of Action 329
R&D Progress 329
aripiprazole - Drug Profile 330
Product Description 330
Mechanism of Action 330
R&D Progress 330
Buprenorphine + Naltrexone - Drug Profile 332
Product Description 332
Mechanism of Action 332
R&D Progress 332
olanzapine - Drug Profile 334
Product Description 334
Mechanism of Action 334
R&D Progress 334
blonanserin - Drug Profile 335
Product Description 335
Mechanism of Action 335
R&D Progress 335
pimavanserin tartrate - Drug Profile 336
Product Description 336
Mechanism of Action 336
R&D Progress 336
blonanserin - Drug Profile 337
Product Description 337
Mechanism of Action 337
R&D Progress 337
acetylcysteine - Drug Profile 338
Product Description 338
Mechanism of Action 338
R&D Progress 338
nalmefene - Drug Profile 339
Product Description 339
Mechanism of Action 339
R&D Progress 339
Psychiatric Disorders Therapeutics – Drug Profile Updates 340
Psychiatric Disorders Therapeutics – Discontinued Products 367
Psychiatric Disorders Therapeutics - Dormant Products 380
Psychiatric Disorders – Product Development Milestones 420
Featured News & Press Releases 420
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases 420
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases 420
Oct 02, 2012: Omeros Announces FDA Clearance To Commence Phase I Study Of OMS824 421
Sep 27, 2012: BioLineRx Announces Publication Of EAGLE Study Results Demonstrating BL-1020's Efficacy In Improving Cognitive Function In Schizophrenia Patients 422
Sep 26, 2012: Jansenn Pharma Announces FDA Approval For Supplemental New Drug Application Of Invega Sustenna 423
Sep 24, 2012: BioLineRx Receives Notice Of Allowance From USPTO For New Patent On BL-1020, Extending Patent Protection Until 2031 423
Sep 20, 2012: Avanir Pharma Achieves Commercial Milestones And Provides Clinical Updates On Nuedexta 424
Sep 17, 2012: Sunovion Pharma Announces Launch Of Once-Daily Latuda For Treatment Of Patients With Schizophrenia 425
Sep 17, 2012: vasopharm's Traumatic Brain Injury Drug Exceeds Expectations In Phase IIa Exploratory Clinical Trial 425
Sep 12, 2012: Lundbeck And Otsuka Announce FDA Acceptance For Resubmission Of New Drug Application For Aripiprazole Depot Formulation 426
Appendix 427
Methodology 427
Coverage 427
Secondary Research 427
Primary Research 427
Expert Panel Validation 427
Contact Us 428
Disclaimer 428

List of Tables
Number of Products Under Development for Psychiatric Disorders, H2 2012 23
Products under Development for Psychiatric Disorders – Comparative Analysis, H2 2012 24
Number of Products under Development by Companies, H2 2012 26
Number of Products under Development by Companies, H2 2012 (Contd..1) 27
Number of Products under Development by Companies, H2 2012 (Contd..2) 28
Number of Products under Development by Companies, H2 2012 (Contd..3) 29
Number of Products under Development by Companies, H2 2012 (Contd..4) 30
Number of Products under Development by Companies, H2 2012 (Contd..5) 31
Number of Products under Development by Companies, H2 2012 (Contd..6) 32
Number of Products under Development by Companies, H2 2012 (Contd..7) 33
Number of Products under Development by Companies, H2 2012 (Contd..8) 34
Number of Products under Development by Companies, H2 2012 (Contd..9) 35
Number of Products under Development by Companies, H2 2012 (Contd..10) 36
Number of Products under Development by Companies, H2 2012 (Contd..11) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 46
Comparative Analysis by Late Stage Development, H2 2012 47
Comparative Analysis by Mid Clinical Stage Development, H2 2012 48
Comparative Analysis by Early Clinical Stage Development, H2 2012 49
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 50
Products under Development by Companies, H2 2012 51
Products under Development by Companies, H2 2012 (Contd..1) 52
Products under Development by Companies, H2 2012 (Contd..2) 53
Products under Development by Companies, H2 2012 (Contd..3) 54
Products under Development by Companies, H2 2012 (Contd..4) 55
Products under Development by Companies, H2 2012 (Contd..5) 56
Products under Development by Companies, H2 2012 (Contd..6) 57
Products under Development by Companies, H2 2012 (Contd..7) 58
Products under Development by Companies, H2 2012 (Contd..8) 59
Products under Development by Companies, H2 2012 (Contd..9) 60
Products under Development by Companies, H2 2012 (Contd..10) 61
Products under Development by Companies, H2 2012 (Contd..11) 62
Products under Development by Companies, H2 2012 (Contd..12) 63
Products under Development by Companies, H2 2012 (Contd..13) 64
Products under Development by Companies, H2 2012 (Contd..14) 65
Products under Development by Companies, H2 2012 (Contd..15) 66
Products under Development by Companies, H2 2012 (Contd..16) 67
Products under Development by Companies, H2 2012 (Contd..17) 68
Products under Investigation by Universities/Institutes, H2 2012 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 85
Bristol-Myers Squibb Company, H2 2012 86
F. Hoffmann-La Roche Ltd., H2 2012 87
Abbott Laboratories, H2 2012 88
NsGene A/S, H2 2012 89
Amgen Inc., H2 2012 90
Sanofi-Aventis, H2 2012 91
Eli Lilly and Company, H2 2012 92
Athersys, Inc., H2 2012 93
GlaxoSmithKline plc, H2 2012 94
Tekmira Pharmaceuticals Corp., H2 2012 95
Alkermes, Inc., H2 2012 96
Dainippon Sumitomo Pharma Co., Ltd., H2 2012 97
Taisho Pharmaceutical Co., Ltd., H2 2012 98
Sangamo BioSciences, Inc., H2 2012 99
Otsuka Pharmaceutical Co., Ltd., H2 2012 100
Takeda Pharmaceutical Company Limited, H2 2012 101
Albany Molecular Research, Inc., H2 2012 102
CardioVascular BioTherapeutics, Inc., H2 2012 103
BioLineRx, Ltd., H2 2012 104
Avineuro Pharmaceuticals, Inc., H2 2012 105
Alexza Pharmaceuticals, Inc., H2 2012 106
Zogenix, Inc., H2 2012 107
Novartis AG, H2 2012 108
Aphios Corporation, H2 2012 109
AcelRx Pharmaceuticals, Inc., H2 2012 110
EnVivo Pharmaceuticals, H2 2012 111
Acorda Therapeutics, Inc., H2 2012 112
Astellas Pharma Inc., H2 2012 113
Eisai Co., Ltd., H2 2012 114
Gedeon Richter Plc., H2 2012 115
H Lundbeck A/S, H2 2012 116
Mitsubishi Tanabe Pharma Corporation, H2 2012 117
Nippon Shinyaku Co., Ltd., H2 2012 118
Pfizer Inc., H2 2012 119
Sigma-Tau S.p.A., H2 2012 120
Zydus Cadila Healthcare Limited, H2 2012 121
Shire Plc, H2 2012 122
NuPathe Inc., H2 2012 123
Oxygen Biotherapeutics, Inc., H2 2012 124
Addex Pharmaceuticals, H2 2012 125
Evotec Aktiengesellschaft, H2 2012 126
FAES Farma SA, H2 2012 127
GW Pharmaceuticals plc, H2 2012 128
Anavex Life Sciences Corp., H2 2012 129
AEterna Zentaris Inc., H2 2012 130
Neuralstem, Inc., H2 2012 131
AVANIR Pharmaceuticals, H2 2012 132
Karo Bio, H2 2012 133
Lpath, Inc., H2 2012 134
Neuren Pharmaceuticals Limited, H2 2012 135
NeuroSearch A/S, H2 2012 136
Catalyst Pharmaceutical Partners, Inc., H2 2012 137
NovaDel Pharma, Inc., H2 2012 138
Nuvo Research Inc., H2 2012 139
Corcept Therapeutics Incorporated, H2 2012 140
ACADIA Pharmaceuticals Inc., H2 2012 141
ARYx Therapeutics, H2 2012 142
RegeneRx Biopharmaceuticals, Inc., H2 2012 143
Dongwha Pharm Co., Ltd., H2 2012 144
Biotie Therapies Corp., H2 2012 145
Transition Therapeutics Inc., H2 2012 146
Allon Therapeutics Inc., H2 2012 147
Suven Life Sciences Ltd., H2 2012 148
Newron Pharmaceuticals S.p.A., H2 2012 149
Stem Cell Therapeutics Corp., H2 2012 150
Rexahn Pharmaceuticals, Inc., H2 2012 151
NeuroVive Pharmaceutical AB, H2 2012 152
Jiangsu Nhwa Pharma Corporation, H2 2012 153
Mithridion, Inc., H2 2012 154
Intas Pharmaceuticals Ltd., H2 2012 155
M et P Pharma AG, H2 2012 156
Spectrum Pharmaceuticals, Inc., H2 2012 157
D-Pharm Ltd., H2 2012 158
Avanti Therapeutics, H2 2012 159
Argolyn Bioscience, Inc., H2 2012 160
Arbor Pharmaceuticals, Inc., H2 2012 161
KeyNeurotek Pharmaceuticals AG, H2 2012 162
Snowdon Inc., H2 2012 163
Domain Therapeutics, H2 2012 164
Ironwood Pharmaceuticals, Inc., H2 2012 165
Abiogen Pharma S.p.A., H2 2012 166
Celon Pharma Sp. z o.o., H2 2012 167

List of Figures
Number of Products under Development for Psychiatric Disorders, H2 2012 23
Products under Development for Psychiatric Disorders – Comparative Analysis, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 38
Late Stage Products, H2 2012 47
Mid Clinical Stage Products, H2 2012 48
Early Clinical Stage Products, H2 2012 49
Discovery and Pre-Clinical Stage Products, H2 2012 50
Assessment by Monotherapy Products, H2 2012 230
Assessment by Combination Products, H2 2012 231
Assessment by Route of Administration, H2 2012 232
Assessment by Stage and Route of Administration, H2 2012 233
Assessment by Molecule Type, H2 2012 234
Assessment by Stage and Molecule Type, H2 2012 235

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos